Department of Ophthalmology, Institute for Biomedical and Clinical Sciences, Linköping University, 58183, Linköping, Sweden.
Department of Biomedical Engineering, Linköping University, 58185, Linköping, Sweden.
Sci Rep. 2020 Oct 9;10(1):16936. doi: 10.1038/s41598-020-73730-9.
Biomaterials designed to replace the diseased cornea could be used to treat corneal blindness where human donor tissue is in short supply, but challenges are the integration of biomaterials with host tissue and cells, avoiding a rapid material degradation and maintaining corneal transparency. Additionally, implantation surgery often triggers an aggressive wound healing response that can lead to corneal thinning and opacity. Here, we report a collagen-based hydrogel with transparency and mechanical properties suitable for replacing a substantial portion of a damaged or diseased corneal stroma. The porous hydrogel permitted migration and population by host cells while maintaining transparency and thickness six months after surgical implantation in an in vivo model of human corneal surgery. With a novel hybrid surgical implantation technique inspired by LASIK refractive surgery, rapid wound healing occurred around implants to maintain biomaterial integrity, transparency and function. Host stromal cell repopulation and regeneration of host epithelium and nerves were observed, as necessary steps towards corneal regeneration. Finally, as a proof-of-principle, the hydrogel loaded with a neuroregenerative drug achieved sustained slow-release drug delivery in vitro. The proposed hydrogel and novel implantation technique together represent a therapeutic approach with translational potential for replacing and regenerating diseased corneal stromal tissue.
旨在替代病变角膜的生物材料可用于治疗因供体组织短缺而导致的角膜盲,但面临的挑战是生物材料与宿主组织和细胞的整合,避免材料快速降解和保持角膜透明性。此外,植入手术通常会引发剧烈的伤口愈合反应,导致角膜变薄和混浊。在这里,我们报告了一种基于胶原蛋白的水凝胶,具有透明性和机械性能,适用于替代受损或患病的大部分角膜基质。多孔水凝胶允许宿主细胞迁移和增殖,同时在体内人角膜手术模型中保持透明度和厚度六个月。采用受 LASIK 屈光手术启发的新型混合手术植入技术,在植入物周围迅速发生伤口愈合,以保持生物材料的完整性、透明度和功能。观察到宿主基质细胞的再增殖以及宿主上皮和神经的再生,这是角膜再生的必要步骤。最后,作为原理验证,负载神经再生药物的水凝胶在体外实现了持续的缓慢药物释放。所提出的水凝胶和新型植入技术共同代表了一种具有转化潜力的治疗方法,可用于替代和再生病变的角膜基质组织。